Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 11/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 4/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29746390 | 1.00 | TTK (0.42) | TTKGSK3BDYRK1AMAP2K4RET | |
| SCHEMBL19950410 | 0.84 | CREBBP (0.41) | GSK3BDYRK1ACREBBP | |
| SCHEMBL20804312 | 0.83 | AXL (0.46) | TTKMAP2K4RETCCNA2CDK2 | |
| SCHEMBL19965543 | 0.82 | MAP2K4 (0.41) | MAP2K4GPR119 | |
| SCHEMBL24591286 | 0.81 | MAP2K4 (0.37) | MAP2K4RET | |
| SCHEMBL19950137 | 0.81 | GPR119 (0.39) | MAP2K4RETGPR119 | |
| SCHEMBL20791779 | 0.81 | RET (0.42) | TTKRET | |
| SCHEMBL29746518 | 0.81 | GPR119 (0.39) | MAP2K4RETGPR119 | |
| SCHEMBL24148625 | 0.81 | AXL (0.46) | TTKGSK3BDYRK1AMAP2K4RET | |
| SCHEMBL19950549 | 0.80 | MAPT (0.39) | MAP2K4RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| CN-115819417-A | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4119558-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Incyte Corporation (US) | 2023-01-18 | — | — | EP | disclosed |
| EP-4119558-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Incyte Corporation (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-109923114-B | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-3510032-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORP (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3510032-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | Incyte Corporation (US) | 2019-07-17 | — | — | EP | disclosed |
| US-10266530-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266530-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190106419-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-04-11 | — | — | US | disclosed |
| US-20190106419-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-04-11 | — | — | US | disclosed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| WO-2018049200-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049200-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | TTK 371/4885GSK3B 2319/4885DYRK1A 3075/4885 |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | TTK 371/4885GSK3B 2319/4885DYRK1A 3075/4885 |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | TTK 371/4885GSK3B 2319/4885DYRK1A 3075/4885 |
| US-20190106419-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | TTK 371/4885GSK3B 2319/4885DYRK1A 3075/4885 |
| US-10266530-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | TTK 371/4885GSK3B 2319/4885DYRK1A 3075/4885 |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | TTK 371/4885GSK3B 2319/4885DYRK1A 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.